tetano
Editor, Senior Moderator
E Kissling [SUP]1[/SUP] [SUP]2[/SUP] , M Rondy [SUP]1[/SUP] [SUP]2[/SUP] , I-MOVE/I-MOVE+ study team [SUP]3[/SUP] + Author affiliations
1. EpiConcept, Paris, France
2. Both authors have contributed equally to the study and manuscript writing
3. The members of I-MOVE/I-MOVE+ study team are listed at the end of the article
Correspondence: Esther Kissling ()
Citation style for this article: Kissling E, Rondy M, I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7)
ii=30464. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.7.30464
Received:09 February 2017; Accepted:16 February 2017
[h=4][/h]
We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0?14, 15?64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65?79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22718
1. EpiConcept, Paris, France
2. Both authors have contributed equally to the study and manuscript writing
3. The members of I-MOVE/I-MOVE+ study team are listed at the end of the article
Correspondence: Esther Kissling ()
Citation style for this article: Kissling E, Rondy M, I-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7)
ii=30464. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.7.30464Received:09 February 2017; Accepted:16 February 2017
[h=4][/h]
We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0?14, 15?64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65?79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22718